CTRI/2022/04/041875已完成未知
Evaluating the safety and efficacy of the probiotic Bifidobacteriumlongum ES1 and the post biotic heat-treated Bifidobacterium longumES1 (HT-ES1) on IBS symptom severity in patients with diarrhoea predominant Irritable Bowel Syndrome
Dr Malwina Naghibi0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Males and females aged =18 to = 65 years.
- •2 Participants diagnosed with diarrhoea-predominant irritable bowel syndrome (IBS-D) as per ROME IV criteria:
- •i) Recurrent abdominal pain on average at least one day/week in the last three months, associated with two or more of the following criteria:
- •Related to defecation
- •Associated with a change in stool frequency (increase/decrease in frequency).
- •Associated with a change in the form (appearance) of stool.
- •ii) History of abnormal bowel movements predominantly diarrhoea ( >25% of bowel movement categorised as stool form type 6 or 7 (diarrhoea) and <25% as stool form type 1 or 2 constipation) on BSFS).
- •3 Participants with an IBS-SSS score = 175.
- •4 Participants who test negative for COVID-19 by Rapid Antigen Lateral Flow Test Device.
- •5 Participants who can comply and perform the procedures as per the protocol (consumption of study medications, biological sample collection procedures, and study visit schedule).
- •Female participants who are willing to use acceptable contraceptives during the study duration.
- •6 Participants who are literate enough to understand the purpose of the study and their rights.
- •7 Participants who are able to give written informed consent and are willing to participate in the study.
排除标准
- •1 Participants diagnosed with anxiety as assessed by STAI-AD S- anxiety subscale score = 40.
- •2 Gluten and/or lactose intolerant individuals.
- •3 Abnormal Thyroid Stimulating Hormone (TSH) value which is ( < 0.4 to > 4.2 mIU/L).
- •4 Participants with uncontrolled type II diabetes mellitus defined as random blood glucose (RBG) > 199 mg/dL or fasting blood glucose (FBG) >125 mg/dL.
- •5 Participants with a body mass index (BMI) = 30 kg/m2.
- •6 Presence of uncontrolled hypertension defined as systolic blood
- •pressure (SBP) = 140 mm Hg and/or diastolic blood pressure (DBP) = 90 mm Hg.
- •7 Participants with a history of intake of antibiotics (Rifaximin, metronidazole, or any other), other probiotics, prebiotics, synbiotic, proton pump inhibitors, acid sequestrants (cholestyramine, Bile colestipol), FODMAP diet, and histamine H2- receptor antagonists/H2 blockers within six weeks prior to the screening day.
- •8 Participants with a history of daily intake of antidepressants (Tricyclic antidepressants, Selective serotonin reuptake inhibitors (SSRIs), and Selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs)), clonidine, otilonium bromide, asimadoline, eluxadoline, diphenoxylate, antispasmodics including mebeverine and pinnaverium and anticholinergics within two weeks before the screening day.
- •9 Participants with a history of bariatric surgery or surgical resection of
- •the stomach, small intestine, or large intestine.
- •10 Participants showing signs of bile acid malabsorption (BAM), as evident from the history of green colour or foul odour of the stool during the last month.
- •11 Participants with a history of or complications from malignant tumours.
- •12 Participation in other clinical trials in the last 90 days prior to screening
- •13 Active smokers or using any form of smokeless tobacco.
- •14 Participants with substance abuse problems (within two years) defined as:
- •15 Use of recreational drugs (such as cocaine, methamphetamine,
- •marijuana, etc.)/Nicotine dependence.
- •16 High-risk drinking as defined by the consumption of four or more alcohol-containing beverages on any day or eight or more alcohol- containing beverages per week for women and five or more alcohol-containing beverages on any day or 15 or more alcohol- containing beverages per week for men.
- •17 Participants having clinically significant illnesses of cardiovascular, endocrine, immune, respiratory, hepato-biliary, kidney and urinary, haematological, musculoskeletal system and/or any inflammatory disorder, tumour, and other gastrointestinal diseases.
研究者
相似试验
尚未招募
3 期
Effect of nutritional supplement in obesityCTRI/2024/04/065821Seven Turns Pvt Ltd
已完成
不适用
The effect of probiotic and fluoride mouthwashes on dental plaqueISRCTN27684426Damascus University30
已完成
3 期
Probiotic in ROUX_en_Y obesity surgery on gastrointestinal function and metabolic factors and weight changesIRCT20220702055340N1Esfahan University of Medical Sciences134
已完成
不适用
evaluation the effect of probiotic on treatment of ADHD childreADHD.Attention-deficit hyperactivity disorder, unspecified typeF90.9IRCT20181022041407N1Mashhad University of Medical Sciences60
已完成
2 期
Effect of probiotic administration on male infertilityIdiopathic male infertility.Male infertility, unspecifiedN46.9IRCT20190824044599N1Artesh University of Medical Sciences60